Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avelumab with Radiation in Transformed IDH Mutant Glioblastoma
NCT02968940Phase 2Completed
- Sponsor
- NYU Langone Health
- Start
- Mar 2017
- Primary completion
- Aug 2019
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of avelumab in glioblastoma (GBM), sponsored by NYU Langone Health. Primary endpoints: Number of Dose Limiting Toxicities at Day 28 and Median Progression-free Survival at 6 Months. Started Mar 2017; status: completed.
02
Drugs
avelumab
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT02968940.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02968940.